Status:
COMPLETED
FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period
Lead Sponsor:
Bayer
Conditions:
Overactive Bladder
Eligibility:
All Genders
18+ years
Brief Summary
Patient perspective on Overactive Bladder and symptoms experienced after administration of Darifenacin
Eligibility Criteria
Inclusion
- Male and female patients \> 18 years with symptoms of overactive bladder.
Exclusion
- Contraindications for the treatment with Darifenacin prolonged-release tablets according to the registered package insert.
- Pregnancy and lactation. Women of childbearing potential have to use an acceptable method of contraception.
- Concomitant treatment with drugs known to affect mainly the urinary bladder function (e.g. anticholinergics, antispasmodics) at any time during the study. Concomitant treatment with botulinum toxin, capsaicin or resiniferatoxin at any time during the study and treatment with botulinum toxin, capsaicin or resiniferatoxin in the last 6 months prior to Visit 1.
Key Trial Info
Start Date :
June 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00921245
Start Date
June 1 2007
End Date
February 1 2009
Last Update
April 20 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, South Africa